MAIAHealthcare · Biotechnology

MAIA Stock Forecast: MAIA Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$1.15

−2.54% on the day

The 1 Wall Street analysts covering MAIA Biotechnology, Inc. hold a median 12-month price target of $12 — +943.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$73.5M

Ticker Nerd rank

23 / 100

Median analyst target

$12

Analysts covering

Revenue$0.0

Operating income−$8.1M

Net income−$7.9M

Free cash flow−$6.8M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−1.7%

−12.2%

YTD

−24.8%

−36.5%

From 52W high

−61.0%

From 52W low

+32.0%

$0.87

$2.95

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MAIA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MAIA Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Value

Accruals

Momentum

Quality

Volatility

Revisions

Issuance

Growth

Size (78): Smaller than most of the companies we track.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MAIA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MAIA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $10Median $12High $14

The green dot is the last close — the median target sits +943.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
21 Feb 2023	Noble Capital Markets	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MAIA appears on the weeks it earns a place.

Performance

MAIA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, MAIA Biotechnology, Inc. returned −36.5% against +16.2% for the S&P 500, dividends included.

MAIA vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MAIA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

MAIA Biotechnology, Inc. (MAIA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.7×
Price / sales: —
Price / book: 3.5×
EV / EBITDA: −1.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −218.7%
Return on assets: −92.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MAIA Biotechnology, Inc. (MAIA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

MAIA Biotechnology, Inc. has a market value of $73.5M and an enterprise value of $44.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$26.8M.
Free cash flow in the twelve months to 30 June 2026: −$22.6M.
Shares outstanding: 60.8M.
Trailing P/E: −1.7×; forward P/E: 1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MAIA Biotechnology, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

MAIA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
MAIAMAIA Biotechnology, Inc.	$73.5M	23
TENXTenax Therapeutics, Inc.	$69.6M	21
FBIOFortress Biotech, Inc.	$69.4M	76
CSBRChampions Oncology, Inc.	$68.7M	28
CINGCingulate, Inc.	$71.0M	45
GANXGain Therapeutics, Inc.	$68.2M	31
HRTXHeron Therapeutics, Inc.	$68.0M	45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MAIA Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MAIA news & analysis

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

GlobeNewsWire · 7 Oct 2026positive

MAIA Biotechnology completed enrollment in Part C of its THIO-101 Phase 2 study and reached 65% of its 2026 enrollment target in the pivotal THIO-104 Phase 3 study, both in non-small cell lung cancer.

Why it matters — The milestones provide updates on enrollment progress in MAIA’s ongoing Phase 2 and pivotal Phase 3 clinical trials.

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

GlobeNewsWire · 1 Oct 2026neutral

Diamond Equity Research, a firm focused on small-cap public companies, has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary was commissioned by MAIA Biotechnology and produced by Diamond Equity Research.

Why it matters — MAIA watchers would be interested in the new coverage and analysis provided by an equity research firm, which may offer additional scrutiny of the company.

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

GlobeNewsWire · 23 Sept 2026positive

MAIA Biotechnology received regulatory approval from Spain's AEMPS and Portugal's INFARMED to begin screening patients in Spain and Portugal for its pivotal Phase 3 THIO-104 clinical trial in non-small cell lung cancer. The trial is advancing toward a key 2027 interim survival analysis.

Why it matters — Expanding the THIO-104 trial into new countries increases the enrollment pool and moves the study forward toward its planned 2027 interim survival analysis.

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

GlobeNewsWire · 22 Sept 2026positive

MAIA Biotechnology announced that enrollment in its pivotal Phase 3 trial THIO-104 has reached 65 patients, evaluating its novel telomere-targeting therapy as a third-line treatment for advanced non-small cell lung cancer. The company also reported a 90.5% disease control rate for the therapy sequenced with a checkpoint inhibitor in heavily pretreated NSCLC patients.

Why it matters — Strong enrollment pace advances the trial toward regulatory milestones and the reported 90.5% disease control rate signals encouraging efficacy data for MAIA's lead candidate.

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

GlobeNewsWire · 16 Sept 2026positive

MAIA Biotechnology announced it has dosed the first U.S. patient in its ongoing Phase 2 clinical trial for non-small cell lung cancer. The milestone follows FDA clearance of the company's amended investigational new drug submission, which highlighted improved manufacturing capabilities and efficiencies.

Why it matters — This marks clinical trial progress in the U.S. and regulatory clearance of manufacturing improvements, signaling advancement in MAIA's lead development program.

FAQ

Frequently asked questions about MAIA stock

What is the MAIA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering MAIA Biotechnology, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MAIA stock a buy right now?

Of the 1 analysts covering MAIA Biotechnology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MAIA Biotechnology, Inc. 23 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MAIA?

As at 8 Oct 2026, MAIA Biotechnology, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

Will MAIA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +943.5% from the last close, and Ticker Nerd's factor model ranks MAIA Biotechnology, Inc. 23 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MAIA stock forecast for 2030?

No analyst covering MAIA Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAIA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has MAIA stock performed over the past year?

MAIA Biotechnology, Inc. returned -36.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MAIA Biotechnology, Inc. do?

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer.

What is the latest news on MAIA?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer". MAIA Biotechnology completed enrollment in Part C of its THIO-101 Phase 2 study and reached 65% of its 2026 enrollment target in the pivotal THIO-104 Phase 3 study, both in non-small cell lung cancer.

Company

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. MAIA Biotechnology concentrates on oncology programs designed to address telomerase-positive cancers, with its lead asset, ateganosine (THIO), an investigational telomere-targeting agent in clinical development for non-small cell lung cancer. The company’s work centers on novel mechanisms of action that combine telomere targeting with immunogenic effects, reflecting a precision-medicine approach to difficult-to-treat tumors. MAIA Biotechnology also advances related second-generation telomere-targeting candidates as part of its current research pipeline. Headquartered in Chicago, Illinois and founded in 2018, MAIA Biotechnology operates within the biotechnology sector and plays a specialized role in the cancer therapeutics market by developing experimental treatments intended for use in oncology and immuno-oncology settings.

CEO Dr. Vlad Vitoc M.B.A., M.D. · 13 employees · United States · https://maiabiotech.com